EDITOR: | May 26th, 2015

Theralase to Present at the 2015 Marcum Microcap Conference

| May 26, 2015 | No Comments
image_pdfimage_print

Theralase-200x125May 26, 2015 (Source: Accesswire) — Theralase Technologies Inc. (“Theralase” or the “Company”) (TSX VENTURE: TLT) (PINKSHEETS: TLTFF),a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 at the Grand Hyatt Hotel in New York City.

The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 1:30 pm ET and will be available via live webcast. To access the webcast, please visit http://wsw.com/webcast/marcum3/tltff.

About the Marcum MicroCap Conference

The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. Industry sectors include Technology, Media & Internet; Software & Business Services; Life Science & Healthcare; Retail & Consumer Products; Energy & Natural Resources; and Industrials. The Marcum MicroCap Conference attracts fund managers and high net worth investors focusing on small cap equities with over 2,000 participants from all segments of the microcap market attending each year.

Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States.

For complete information about the 2015 Marcum MicroCap Conference, visit www.marcumllp.com/microcap.

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase”)(TSX VENTURE: TLT) (PINKSHEETS: TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.


Raj Shah

Editor:

Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>


Copyright © 2017 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Leave a Reply

Your email address will not be published. Required fields are marked *